按估算肾小球滤过率校正的蛋白尿对慢性肾脏病患者终末期肾病风险的重分类:肾内科门诊多中心前瞻性研究
该多中心前瞻性研究纳入3957例G3-G5期非透析慢性肾脏病患者,比较绝对蛋白尿(Uprot)与滤过校正蛋白尿(F-Uprot=Uprot/eGFR×100)对终末期肾病(ESRD)风险的预测能力。中位随访44个月,862例进展至ESRD。F-Uprot在所有CKD分期均显著预测ESRD,而Uprot在G5期预测效果不显著;F-Uprot模型预测性能优于Uprot模型,净重分类改善12.2%(95%CI 4.2-21.1)。
要点
- F-Uprot在所有CKD分期均显著预测ESRD,而Uprot在G5期预测不显著。
- F-Uprot模型较Uprot模型预测ESRD性能更优,净重分类改善12.2%。
- 在老年、糖尿病、心血管疾病及糖尿病肾病、肾小球肾炎、G4-G5期患者中重分类改善更明显。
核心结论
- 在肾内科门诊转诊的显性CKD患者中,F-Uprot在所有分期均预测ESRD,并较Uprot改善肾脏风险重分类,尤其在晚期和复杂疾病中。
研究设计与样本
- 多队列前瞻性研究,纳入3957例转诊至肾内科门诊的G3-G5期非透析CKD患者。
- 分别构建包含Uprot(g/24 h)或F-Uprot(Uprot/eGFR×100,g/24 h per 100 mL/min/1.73 m2 eGFR)的多变量Cox模型预测ESRD风险。
主要发现
- 患者平均年龄67±14岁,男性60%,糖尿病29%,心血管疾病34%,eGFR 32±13 mL/min/1.73 m2,Uprot中位数0.41(IQR 0.12-1.29)g/24 h,F-Uprot中位数1.41(IQR 0.36-4.93)g/24 h per 100 mL/min/1.73 m2 eGFR。
- 中位随访44个月,862例患者达到ESRD。
- 竞争风险分析显示,在G3a-G4期(P < 0.001)和G5期(P = 0.002),F-Uprot为1.0-4.9和≥5.0( vs <1.0 g/24 h per 100 mL/min/1.73 m2 eGFR)时ESRD风险逐步增加。
- 多变量Cox分析显示Uprot在G3a-G4期预测ESRD,但在G5期效应不显著;F-Uprot在所有分期均显著预测ESRD。
- 根据Akaike信息准则,F-Uprot模型预测显著优于Uprot模型;净重分类改善为12.2%(95%CI 4.2-21.1),在老年、糖尿病、心血管疾病、糖尿病肾病、肾小球肾炎及CKD G4和G5期患者中重分类更高。
临床怎么用
- 在肾内科门诊CKD患者中,可采用F-Uprot(Uprot/eGFR×100)替代绝对蛋白尿进行ESRD风险分层,尤其在G4-G5期及合并糖尿病、心血管疾病等复杂患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In non-dialysis chronic kidney disease (CKD), absolute proteinuria (Uprot) depends on the extent of kidney damage and residual glomerular filtration rate (GFR). We therefore evaluated, as compared with Uprot, the strength of association of proteinuria indexed to estimated GFR (eGFR) with end-stage renal disease (ESRD) risk. METHODS: In a multi-cohort prospective study in 3957 CKD patients of Stages G3-G5 referred to nephrology clinics, we tested two multivariable Cox models for ESRD risk, with either Uprot (g/24 h) or filtration-adjusted proteinuria (F-Uprot) calculated as Uprot/eGFR ×100. RESULTS: Mean ± SD age was 67 ± 14 years, males 60%, diabetics 29%, cardiovascular disease (CVD) 34%, eGFR 32 ± 13 mL/min/1.73 m2, median (interquartile range) Uprot 0.41 (0.12-1.29) g/24 h and F-Uprot 1.41 (0.36-4.93) g/24 h per 100 mL/min/1.73 m2 eGFR. Over a median follow-up of 44 months, 862 patients reached ESRD. At competing risk analysis, ESRD risk progressively increased when F-Uprot was 1.0-4.9 and ≥5.0 versus <1.0 g/24 h per 100 mL/min/1.73 m2 eGFR in Stages G3a-G4 (P < 0.001) and Stage G5 (P = 0.002). Multivariable Cox analysis showed that Uprot predicts ESRD in Stages G3a-G4 while in G5 the effect was not significant; conversely, F-Uprot significantly predicted ESRD at all stages. The F-Uprot model allowed a significantly better prediction versus the Uprot model according to Akaike information criterion. Net reclassification improvement was 12.2% (95% confidence interval 4.2-21.1), with higher reclassification in elderly, diabetes and CVD, as well as in diabetic nephropathy and glomerulonephritis, and in CKD Stages G4 and G5. CONCLUSIONS: In patients referred to nephrology clinics, F-Uprot predicts ESRD at all stages of overt CKD and improves, as compared with Uprot, reclassification of patients for renal risk, especially in more advanced and complicated disease.
引用
- Provenzano M, Chiodini P, Minutolo R, et al. Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics. Nephrol Dial Transplant. 2020. PMID: 30053127. doi:10.1093/ndt/gfy217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。